Mendeljev SRL
2.7 FTEThe score of Mendeljev shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +41 % Total assets +21 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Mendeljev's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 86,412 € | ||||
| Equity | 619,912 € | ||||
| Cash | 437,122 € | ||||
| EBITDA | 171,884 € | ||||
| Total assets | €1.14m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jul 2026
- Year ended 31 Dec 2024filed on 01 Aug 2025
- Year ended 31 Dec 2023filed on 25 Jul 2024
- Year ended 31 Dec 2022filed on 12 Jul 2023
- Year ended 31 Dec 2021filed on 26 Jul 2022
Mendeljev's financial analysis
- Solvency54.5%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Mendeljev
Mendeljev's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0830.138.866
- VAT number
- BE0830138866
- Peppol
- Registered · 0208:0830138866 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 06 Oct 2010
- Registered office
- 8730 Beernem
- Size
- Micro · 2.7 FTE
- Latest accounts
- 2025 · filed on 23 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Mendeljev (SRL) has been based in Beernem since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 86,412 € and equity of 619,912 €; its revenue is not published. With 2.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 54.5%, above the median of its sector (44.2%).
Companies similar to Mendeljev
Companies in the same business, of comparable size and area, outside its group.
- Dekerk Retail sale of pharmaceutical products Tienen · balance sheet €1.12m
- Pharmacie Van Gelder Retail sale of pharmaceutical products Colfontaine · balance sheet €1.09m
- Reine Pharma Retail sale of pharmaceutical products Brussels · balance sheet €1.03m
- Apotheek Loksbergen Retail sale of pharmaceutical products Halen · balance sheet €1.15m
- Ma Ressource Santé Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet €1.17m
- W.A. Farma Retail sale of pharmaceutical products Kontich · balance sheet €1.09m
- Sephabel Retail sale of pharmaceutical products Leuven · balance sheet €1.21m
- Farmacie Céline Desmet Retail sale of pharmaceutical products Heuvelland · balance sheet €1.06m
Frequently asked questions about Mendeljev
What is the revenue of Mendeljev?
Mendeljev files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Mendeljev?
In Belgium, the VAT number is the company number prefixed with BE: BE0830138866 for Mendeljev, if the company is VAT-registered. Its company number (CBE) is 0830.138.866.
Where is the registered office of Mendeljev?
According to the CBE register, the registered office of Mendeljev is in 8730 Beernem.
What is the equity of Mendeljev?
At the close of the 2025 financial year, the equity of Mendeljev amounts to 619,912 €, a solvency of 54.5% of total assets.
How many people work at Mendeljev?
2.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Mendeljev?
The register lists 2 active mandates at Mendeljev. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Mendeljev
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →